MADRIGAL PHARMACEUTICALS INC. - COMMON STOCK

Madrigal Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference

03 يناير 2024 16:30:00 بحسب Nasdaq GlobeNewswire

Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

22 ديسمبر 2023 16:30:00 بحسب Nasdaq GlobeNewswire

Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

27 نوفمبر 2023 16:30:00 بحسب Nasdaq GlobeNewswire

Madrigal Pharmaceuticals Appoints Ronald Filippo as Chief Information Officer

21 نوفمبر 2023 08:00:00 بحسب Nasdaq GlobeNewswire

Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

15 نوفمبر 2023 16:45:00 بحسب Nasdaq GlobeNewswire

Madrigal Pharmaceuticals Presents New Data from the Phase 3 MAESTRO-NASH Trial Demonstrating Broad Treatment Effects of Resmetirom on Noninvasive Measures of Liver Health

10 نوفمبر 2023 08:00:00 بحسب Nasdaq GlobeNewswire

Madrigal Pharmaceuticals Appoints Carole Huntsman as Chief Commercial Officer

10 نوفمبر 2023 07:30:00 بحسب Nasdaq GlobeNewswire

Madrigal Pharmaceuticals Provides Corporate Updates and Reports Third Quarter 2023 Financial Results

06 نوفمبر 2023 08:00:01 بحسب Nasdaq GlobeNewswire

Madrigal Pharmaceuticals Announces Participation at Three Upcoming Investor Conferences

02 نوفمبر 2023 16:05:00 بحسب Nasdaq GlobeNewswire

Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

12 أكتوبر 2023 16:05:00 بحسب Nasdaq GlobeNewswire

Madrigal Pharmaceuticals Announces Pricing of $500 Million Public Offering

28 سبتمبر 2023 22:30:00 بحسب Nasdaq GlobeNewswire

Madrigal Pharmaceuticals Announces Proposed Public Offering

28 سبتمبر 2023 16:01:00 بحسب Nasdaq GlobeNewswire

Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

14 سبتمبر 2023 16:30:00 بحسب Nasdaq GlobeNewswire

Madrigal Pharmaceuticals Announces NDA Acceptance and Priority Review of the New Drug Application for Resmetirom for the Treatment of NASH with Liver Fibrosis

13 سبتمبر 2023 09:10:00 بحسب Nasdaq GlobeNewswire

Madrigal Pharmaceuticals Appoints Bill Sibold as Chief Executive Officer

11 سبتمبر 2023 07:00:00 بحسب Nasdaq GlobeNewswire

Madrigal Pharmaceuticals Provides Corporate Updates and Reports Second Quarter 2023 Financial Results

08 أغسطس 2023 08:00:01 بحسب Nasdaq GlobeNewswire

Madrigal Pharmaceuticals Completes Submission of New Drug Application Seeking Accelerated Approval of Resmetirom for the Treatment of NASH with Liver Fibrosis

17 يوليو 2023 08:00:01 بحسب Nasdaq GlobeNewswire

Madrigal Pharmaceuticals Announces Rolling Submission of New Drug Application to U.S. FDA Seeking Accelerated Approval of Resmetirom for the Treatment of NASH with Liver Fibrosis

30 يونيو 2023 08:00:00 بحسب Nasdaq GlobeNewswire

Madrigal Pharmaceuticals Presents Phase 3 MAESTRO-NASH Data During the Opening General Session of the EASL Congress™

22 يونيو 2023 03:30:00 بحسب Nasdaq GlobeNewswire

Madrigal Pharmaceuticals Supports International NASH Day on June 8

06 يونيو 2023 08:00:02 بحسب Nasdaq GlobeNewswire